- Home
- SOL vs ABP Comparison
SOL vs ABP Comparison
Compare SOL & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ABP
- Stock Information
- Founded
- SOL 2005
- ABP 2004
- Country
- SOL United States
- ABP United States
- Employees
- SOL N/A
- ABP N/A
- Industry
- SOL Semiconductors
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- ABP Health Care
- Exchange
- SOL Nasdaq
- ABP Nasdaq
- Market Cap
- SOL 89.7M
- ABP 76.2M
- IPO Year
- SOL 2008
- ABP N/A
- Fundamental
- Price
- SOL $1.66
- ABP $0.84
- Analyst Decision
- SOL Buy
- ABP
- Analyst Count
- SOL 3
- ABP 0
- Target Price
- SOL $3.83
- ABP N/A
- AVG Volume (30 Days)
- SOL 181.6K
- ABP 38.3K
- Earning Date
- SOL 03-27-2025
- ABP 02-28-2025
- Dividend Yield
- SOL N/A
- ABP N/A
- EPS Growth
- SOL N/A
- ABP N/A
- EPS
- SOL N/A
- ABP N/A
- Revenue
- SOL $102,489,000.00
- ABP $230,000.00
- Revenue This Year
- SOL N/A
- ABP N/A
- Revenue Next Year
- SOL $47.66
- ABP N/A
- P/E Ratio
- SOL N/A
- ABP N/A
- Revenue Growth
- SOL 25.98
- ABP N/A
- 52 Week Low
- SOL $1.41
- ABP $0.80
- 52 Week High
- SOL $3.00
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- SOL 36.27
- ABP N/A
- Support Level
- SOL $1.67
- ABP N/A
- Resistance Level
- SOL $1.79
- ABP N/A
- Average True Range (ATR)
- SOL 0.08
- ABP 0.00
- MACD
- SOL -0.00
- ABP 0.00
- Stochastic Oscillator
- SOL 18.52
- ABP 0.00
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.